Maria Antista

1.1k total citations
26 papers, 300 citations indexed

About

Maria Antista is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Cancer Research. According to data from OpenAlex, Maria Antista has authored 26 papers receiving a total of 300 indexed citations (citations by other indexed papers that have themselves been cited), including 15 papers in Oncology, 10 papers in Pulmonary and Respiratory Medicine and 7 papers in Cancer Research. Recurrent topics in Maria Antista's work include Colorectal Cancer Treatments and Studies (7 papers), Gastric Cancer Management and Outcomes (6 papers) and Genetic factors in colorectal cancer (5 papers). Maria Antista is often cited by papers focused on Colorectal Cancer Treatments and Studies (7 papers), Gastric Cancer Management and Outcomes (6 papers) and Genetic factors in colorectal cancer (5 papers). Maria Antista collaborates with scholars based in Italy, United Kingdom and Spain. Maria Antista's co-authors include Filippo Pietrantonio, Giovanni Fucà, Filippo de Braud, Federica Morano, Maria Di Bartolomeo, Sara Lonardi, Francesca Corti, Andrea Spallanzani, Monica Niger and Vittorina Zagonel and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Scientific Reports.

In The Last Decade

Maria Antista

24 papers receiving 293 citations

Peers

Countries citing papers authored by Maria Antista

Since Specialization

Citations

This map shows the geographic impact of Maria Antista's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Maria Antista with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Maria Antista more than expected).

Fields of papers citing papers by Maria Antista

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Maria Antista. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Maria Antista. The network helps show where Maria Antista may publish in the future.

Co-authorship network of co-authors of Maria Antista

This figure shows the co-authorship network connecting the top 25 collaborators of Maria Antista. A scholar is included among the top collaborators of Maria Antista based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Maria Antista. Maria Antista is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Title	Journal	Authors	Indexed citations
1	Effect of aspirin use on cancer incidence and mortality: An updated systematic review and meta-analysis	Public Health	Fausto Petrelli, Antonio Ghidini et al.	0
2	Ralstonia insidiosa Bacteremia in Patients with Solid Cancer Treated by Means of a Central Venous Catheter	SHILAP Revista de lepidopterología	Lorenzo Ruggieri, Anna Lisa Ridolfo et al.	1
3	First line therapy in stage IV BRAF mutated colorectal cancer	Heliyon	Fausto Petrelli, Maria Antista et al.	3
4	Adjuvant and neoadjuvant chemotherapy for MSI early gastric cancer: a systematic review and meta-analysis	Therapeutic Advances in Medical Oncology	Fausto Petrelli, Maria Antista et al.	5
5	Different prognosis of left compared to right breast cancer: A systematic review and meta-analysis	Cancer Epidemiology	Antonio Ghidini, Maria Antista et al.	0
6	Clinical efficacy of the first two doses of anti‐SARS‐CoV‐2 mRNA vaccines in solid cancer patients	Cancer Medicine	Maria Silvia Cona, Agostino Riva et al.	5
7	Plasmatic BRAF-V600E allele fraction as a prognostic factor in metastatic colorectal cancer treated with BRAF combinatorial treatments	Annals of Oncology	Javier Ros, Judit Matito et al.	38
8	Encorafenib plus cetuximab treatment in BRAF V600E-mutated metastatic colorectal cancer patients pre-treated with an anti-EGFR: An AGEO-GONO case series	European Journal of Cancer	Alessandra Boccaccino, Claire Gallois et al.	8
9	Biomarker Landscape in Neuroendocrine Tumors With High-Grade Features: Current Knowledge and Future Perspective	Frontiers in Oncology	Michele Prisciandaro, Maria Antista et al.	6
10	Metastatic pheochromocytomas and paragangliomas: where are we?	Tumori Journal	Natalie Prinzi, Francesca Corti et al.	4
11	The Pan-Immune-Inflammation Value in microsatellite instability–high metastatic colorectal cancer patients treated with immune checkpoint inhibitors	European Journal of Cancer	Francesca Corti, Sara Lonardi et al.	78
12	Tumour mutational burden predicts resistance to EGFR/BRAF blockade in BRAF-mutated microsatellite stable metastatic colorectal cancer	European Journal of Cancer	Giovanni Randon, Rossana Intini et al.	15
13	Assessing safety and activity of cabozantinib combined with lanreotide in gastroenteropancreatic (GEP) and thoracic neuroendocrine tumors (NETs): The phase II LOLA trial.	Journal of Clinical Oncology	Francesca Corti, Vito Amoroso et al.	1
14	The potential role of metformin in the treatment of patients with pancreatic neuroendocrine tumors: a review of preclinical to clinical evidence	Therapeutic Advances in Gastroenterology	Sara Pusceddu, Claudio Vernieri et al.	9
15	402MO Final results of the CARACAS study: Randomized phase II trial of avelumab alone or with cetuximab for unresectable, locally advanced or metastatic squamous cell anal carcinoma progressed to at least one line of treatment	Annals of Oncology	Sara Lonardi, Filippo Pietrantonio et al.	13
16	One size does not fit all for pancreatic cancers: A review on rare histologies and therapeutic approaches	World Journal of Gastrointestinal Oncology	Monica Niger, Michele Prisciandaro et al.	13
17	Metronomic Capecitabine With Cyclophosphamide Regimen in Unresectable or Relapsed Pseudomyxoma Peritonei	Clinical Colorectal Cancer	Alessandra Raimondi, Salvatore Corallo et al.	11
18	The landscape of d16HER2 splice variant expression across HER2-positive cancers	Scientific Reports	Chiara Costanza Volpi, Filippo Pietrantonio et al.	23
19	Prognostic and Predictive Value of Microsatellite Instability, Inflammatory Reaction and PD-L1 in Gastric Cancer Patients Treated with Either Adjuvant 5-FU/LV or Sequential FOLFIRI Followed by Cisplatin and Docetaxel: A Translational Analysis from the ITACA-S Trial	The Oncologist	Maria Di Bartolomeo, Federica Morano et al.	38
20	Is MGMT methylation a new therapeutic target for biliary tract cancer?	Annals of Oncology	Monica Niger, Federica Morano et al.	1

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact